Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2016

View Archived Issues

Amcure treats first patient in phase I/Ib study of AMC-303

Medivir selects MIV-818 as candidate drug for hepatocellular carcinoma

Novartis initiates phase I/II trial of BLZ-945 in advanced solid tumors

OncoVent initiates clinical development program for AR20.5 for the treatment of pancreatic cancer

Sumitomo Dainippon announces development highlights of second quarter of fiscal 2016

Discovery and characterization of novel first-generation CFTR corrector GLPG-2222

Responses seen with anti-fucosyl-GM1 MAb BMS-986012 in small cell lung cancer

Verastem obtains license to duvelisib

Galapagos presents promising data for novel CFTR potentiator GLPG-1837

Bristol-Myers Squibb reflects on milestones of third quarter 2016

Durect reports first clinical data on DUR-928 in patients with NASH

Novo Nordisk reflects on accomplishments of third quarter 2016

MorphoSys and Leo Pharma collaborate to develop therapeutic antibodies in dermatology

Phase I data reported for TNFRSF4 agonist MEDI-0562 in patients with solid tumors

AbbVie presents TNF-alpha modulators

Genomic Health reports clinical validation study results for Oncotype DX Genomic Prostate Score

FORMA Therapeutics patents HDAC inhibitors

SIMM reports development of mGlu5 receptor modulators

Opiant Pharmaceuticals licenses heroin vaccine from WRAIR and NIDA

Signal Genetics and miRagen Therapeutics enter merger agreement

EnBiotix acquires AMP Therapeutics' antimicrobial peptide portfolio

Omeros reports on phase II trial of PPARgamma agonist in heroin-dependent subjects

Medivir to acquire two Tetralogic oncology programs

Gilead terminates development of simtuzumab and GS-5745 for ulcerative colitis and Crohn's disease

Drug discovery company Bridge Medicines launched in partnership with Takeda

Investigators identify novel causative mutations in mucopolysaccharidosis type IV patients

ValiRx updates progress of phase II trial of VAL-401

Therapeutic potential of 177Lu-labeled chimeric antibody NNV-009 in NHL and CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...